Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study
Journal of Orthopaedic Surgery · 2026-05 · 34 (2)
DOI: 10.1177/10225536261470877 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Orthopaedic Surgery, online erschienen am 17.07.2026. Verfasst von Qinglong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spinal Surgery and Neurosurgery, Sichuan Provincial Orthopedic Hospital, Chengdu, China. Hauptthemen laut MEDLINE: Denosumab, Zoledronic Acid, Bone Density, Bone Density Conservation Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
To compare the real-world effectiveness and safety of denosumab versus zoledronic acid in postmenopausal osteoporosis (PMO) and characterize baseline fracture risk profiles.
Methods
This retrospective cohort study included 250 PMO patients treated with denosumab (n = 148) or zoledronic acid (n = 102). Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates. The primary endpoint was 12-month change in lumbar spine bone mineral density (BMD). Fracture risk status was descriptively analyzed.
Results
The cohort was predominantly high-risk (98.4%). IPTW achieved adequate covariate balance. At 12 months, denosumab showed greater increases in lumbar spine BMD than zoledronic acid (6.09% vs. 4.82%; difference 1.27%, 95% CI: 0.474–2.067; P = 0.002), with consistent findings at the hip. Most adverse events were comparable between groups; however, acute phase reaction occurred significantly less frequently with denosumab, while no differences were observed in hypocalcemia or renal events.
Conclusion
Denosumab was associated with greater BMD gains than zoledronic acid over 12 months, with broadly comparable safety in a real-world PMO population. These findings are limited to short-term BMD outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Spinal Surgery and Neurosurgery, Sichuan Provincial Orthopedic Hospital, Chengdu, China.
ORCID-Profile: Simao Song
Zitieren
APA
Li, Q., Shi, H., Hou, W., Gu, T., & Song, S. (2026). Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study. Journal of Orthopaedic Surgery, 34(2). https://doi.org/10.1177/10225536261470877
Vancouver
Li Q, Shi H, Hou W, Gu T, Song S. Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study. Journal of Orthopaedic Surgery. 2026;34(2). doi:10.1177/10225536261470877
BibTeX
@article{Li2026,
author = {Li, Qinglong and Shi, Huagang and Hou, Wei and Gu, Tao and Song, Simao},
title = {Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study},
journal = {Journal of Orthopaedic Surgery},
year = {2026},
volume = {34},
number = {2},
doi = {10.1177/10225536261470877}
}
EUVIMED